Fabry Disease Diagnosis

Fabry disease is an X-linked recessive disorder that leads to the accumulation of a lipid called globotriaosylceramide in the cells of the body. The condition is rare and affects around 1 in 50,000 males. As an X-linked condition, Fabry disease mainly affects males, although females can also be affected.

Although symptoms generally develop during childhood, they can go unrecognized until later on in adulthood when the vital organs are already involved. Since the disease is progressive and can be life threatening, it is important to diagnose Fabry disease as early as possible. Patients with a family history of Fabry disease should be tested for the condition regardless of their symptom profile.


The steps taken to diagnose this disease are described below.

Presumptive diagnosis

A presumptive diagnosis can be made based on evaluation of the patient’s symptoms. Typical features of this condition include pain in the hands and feet, dark red spots on the skin called angiokeratomas, a decrease in sweat function (hypohidrosis), opaque cornea, hearing loss, gastrointestinal complaints and tinnitus. The patient is also asked about any family history of the condition or symptoms of the condition among other family members.

Biochemical diagnosis

  • Enzymatic assay – The globotriaosylceramide accumulation that occurs in Fabry disease is caused by a deficiency in the enzyme α galactosidase A (α-GAL A). In males, the level of α-GAL A activity in the plasma, leukocytes, tears, or tissue can be tested using a synthetic substrate for the enzyme and a diagnosis confirmed by a low or undetectable level of α-GAL A activity. The measurement of α-GAL A is not as useful for confirming a diagnosis in affected females or carriers of the disease because these individuals often have a normal level of α-GAL A activity.
  • The α-GAL A deficiency is caused by a mutation in the GLA gene. Most of the mutations that have been identified so far are inherited mutations. Linkage analysis of the GLA gene is the most reliable way of confirming a diagnosis in females.
  • Females can also be diagnosed in cases of low or absent α-GAL A activity accompanied by lipid laden biopsied tissue or urinary sediment.

Further Reading

Last Updated: Feb 26, 2019

Dr. Ananya Mandal

Written by

Dr. Ananya Mandal

Dr. Ananya Mandal is a doctor by profession, lecturer by vocation and a medical writer by passion. She specialized in Clinical Pharmacology after her bachelor's (MBBS). For her, health communication is not just writing complicated reviews for professionals but making medical knowledge understandable and available to the general public as well.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Mandal, Ananya. (2019, February 26). Fabry Disease Diagnosis. News-Medical. Retrieved on August 10, 2022 from https://www.news-medical.net/health/Fabry-Disease-Diagnosis.aspx.

  • MLA

    Mandal, Ananya. "Fabry Disease Diagnosis". News-Medical. 10 August 2022. <https://www.news-medical.net/health/Fabry-Disease-Diagnosis.aspx>.

  • Chicago

    Mandal, Ananya. "Fabry Disease Diagnosis". News-Medical. https://www.news-medical.net/health/Fabry-Disease-Diagnosis.aspx. (accessed August 10, 2022).

  • Harvard

    Mandal, Ananya. 2019. Fabry Disease Diagnosis. News-Medical, viewed 10 August 2022, https://www.news-medical.net/health/Fabry-Disease-Diagnosis.aspx.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment